RxDoctor Payments Data

Jillian Wawrzyniak, MD

Family Medicine · Phoenixville, PANPI 1508128398

Payments from drug & device makers

$885in general payments, 2019–2025

Across 59 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$220
  • Amgen$199
  • Mallinckrodt Enterprises LLC$134
  • AstraZeneca$64
  • Novo Nordisk$38
  • Jazz Pharmaceuticals Inc.$34
  • plus $196 from 9 others

What the payments were for

  • Food & beverage$885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$885 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$117,017
Medicare patients
469
Services billed
2,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$130,561
JardianceEmpagliflozin62$79,522
Enbrel SureclickEtanercept11$76,938
FarxigaDapagliflozin Propanediol50$71,501
JanuviaSitagliptin Phosphate77$70,069
OzempicSemaglutide42$52,614
TradjentaLinagliptin49$45,537
XareltoRivaroxaban32$41,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$39,480
CreonLipase/Protease/Amylase16$38,102
Breo ElliptaFluticasone/Vilanterol63$31,619
LinzessLinaclotide19$20,317
MounjaroTirzepatide12$11,908
JanumetSitagliptin Phos/Metformin Hcl12$10,661
MyrbetriqMirabegron18$10,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$14$133,369128 claims
AstraZenecaFarxiga$64$71,50150 claims
GSKTrelegy Ellipta, Breo Ellipta$29$71,099114 claims
AbbVieCreon, Linzess, Synthroid$220$64,030132 claims
Novo NordiskOzempic$38$52,61442 claims
Lilly USA, LLCMounjaro$28$11,90812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Phoenixville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →